<DOC>
	<DOCNO>NCT01772797</DOCNO>
	<brief_summary>The primary purpose study estimate maximum tolerate dose combination LDK378 AUY922 . This study ass safety , tolerability , pharmacokinetics preliminary evidence anti-tumor activity combination LDK378 AUY922 ALK-rearranged non-small cell lung cancer .</brief_summary>
	<brief_title>Phase Ib Study LDK378 AUY922 ALK-rearranged Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>locally advanced metastatic NSCLC progress follow therapy ALK inhibitor tumor must carry ALK rearrangement 15 % tumor cell measure FISH disease evaluate RECIST v1.1 measurable disease central nervous system ( CNS ) metastases symptomatic require increase steroid CNSdirected therapy control CNS disease history interstitial lung disease interstitial pneumonitis , include clinically significant radiation pneumonitis clinically significant cardiac dysfunction inadequate end organ function define specified laboratory value use medication know strong inhibitor inducters CYP3A4/5 discontinue least 1 week prior start treatment use medication mainly metabolize CYP3A4/5 CYP2C9 discontinue least 1 week prior start treatment clinically significant , uncontrolled impair gastrointestinal function GI disease prior treatment HSP90 inhibitor radiotherapy lung within 4 week prior first dose study treatment patient recover radiotherapyrelated toxicity pregnant nursing woman history pancreatitis history increase amylase lipase due pancreatic disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>anaplastic lymphoma kinase , ALK-rearranged lung cancer , non-small cell lung cancer</keyword>
</DOC>